This article identifies the connections between the erotic, power, gender and oppression. Addresses the possibility for changing sexual behavior as well as sexual attitudes.
Read the New View Campaign’s comments on US FDA hearings for approval of Flibanserin:
“On June 18, 2010, the FDA Reproductive Health Advisory Committee convenes for the second time to consider a drug for "female sexual dysfunction" (the first drug, Intrinsa, failed in 2004). The New View Campaign opposes the approval of flibanserin, and is preparing factsheets and petitions, has spoken to endless media, and will be participating in the hearing as part of the section on public speakers. In combination with the materials we prepared in 2004 for the Intrinsa hearing, these resources offer a rich analysis of the medicalization of sexuality.”
Reviews recently published recommendations for revision of definitions of women's sexual disorders that combine interpersonal, contextual, personal psychological and biological factors.
Examines the medical bias towards female sexual problems and provides advice to women suffering from a decrease or loss of sexual desire and enjoyment.
Introduces an educational campaign that challenges the myths promoted by the pharmaceutical industry and calls for research on the many causes of women's sexual problems.
